Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Akoya Biosciences Q3 Earnings

Akoya Biosciences (NASDAQ:AKYA) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM. Here’s what…
byBenzinga Insights
November 8, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Akoya Biosciences (NASDAQ:AKYA) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Akoya Biosciences beat estimated earnings by 29.73%, reporting an EPS of $-0.26 versus an estimate of $-0.37.

Revenue was up $6.36 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.07 which was followed by a 3.01% increase in the share price the next day.

Here’s a look at Akoya Biosciences’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.44 -0.48 -0.43 -0.43
EPS Actual -0.51 -0.49 -0.50 -0.47
Revenue Estimate 22.17M 20.32M 20.58M 17.71M
Revenue Actual 23.52M 21.41M 21.22M 18.85M

To track all earnings releases for Akoya Biosciences visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD Giant’s Challenging Year: Q4 Net Sales Slide By 27% But Net Loss Narrows 67% YoY

By Jelena Martinovic
December 26, 7:05 PM
cbdMD reported a 27% year-over-year drop in net sales for the fourth quarter of 2023, totaling $5.7 million. The company attributed the decline to industry trends, reduced marketing spend, and lower wholesale pricing for its new high-strength products. For the full fiscal year 2023, net sales reached $24.2 million, down from $35.4 million in the previous year. Gross profit for the year was approximately $15 million, a decrease from $22.3 million in fiscal 2022. The company reported a net loss of about $23 million, compared to $70 million in 2022. Operating expenses fell to $24.2 million from $40 million in the prior year. cbdMD's working capital on September 30, 2023, was $3.4 million, down from $10.7 million on the same date in 2022. The company also launched its hempMD and ATRx brands in 2023, expanding its product channels into Amazon and other consumer products channels.

YCBD